Actualités

Johnson & Johnson (NYSE:JNJ) received positive regulatory developments in Europe for multiple myeloma therapy Tecvayli used in combination with Darzalex SC, supported by phase III trial data. The company agreed to acquire Firefly Bio to expand its cancer drug pipeline into next generation oncology treatments. A Los Angeles jury delivered a verdict in favor of Johnson & Johnson in a key talc litigation case related to ovarian cancer. Johnson & Johnson sits at the intersection of...

Most parents approach a wedding as a bill. Save the money, write the checks, and move on. Investors can look at it differently. Instead of asking how much the wedding will cost, ask how much capital would be required to generate that amount from portfolio income. The answer reveals something interesting: the wedding lasts one ... The Portfolio That Pays For Your Daughter’s Wedding

JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.

Hearing aids restore conversations. Dental work restores smiles. Vision correction restores independence. Many of the expenses Medicare leaves uncovered sit at the intersection of appearance, confidence, and daily quality of life. Unfortunately, all those things cost money. Big money. So here’s how to close the gap in your budget… and your teeth. What Medicare Leaves ... Medicare Keeps You Alive. This Portfolio Keeps You Looking Good.

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

The median U.S. household income is roughly $50,000 a year. It’s also a common floor for a livable retirement budget once Social Security benefits are layered on top. Replacing it with dividends alone is a math problem before it is a stock-picking problem, and the inputs are blunt: The yield you accept determines the capital ... Here’s How Much Money You Need to Replace a $50,000 Income With Dividends

The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.

It can provide some stability during volatile times.

Dow Jones medical giant Johnson & Johnson are breaking out past its latest buy point, while Iron Mountain, PNC and Fortinet are in buy zones.

Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.

Earned income demands your time. Passive income asks only that you stay invested. Dividend stocks remain the cornerstone of retirement portfolios because a check that arrives whether you worked Monday or not feels fundamentally different from a paycheck. Real estate offers similar cash flow but locks capital behind tenants, repairs, and illiquid mortgages. Dividend stocks ... These 5 Passive Income Stocks Could Pay You For Life

The Bureau of Labor Statistics puts the median electrician at roughly $62,000 a year, while many experienced electricians earn $65,000 to $80,000 or more once overtime enters the picture. Replacing that paycheck with dividend income is the question this article answers. The math is straightforward: income target divided by yield equals capital required. For simplicity, ... Take Home an Electrician’s Paycheck Without the High Voltage

COO's premium lenses, MiSight and fertility trends support growth, but Asia-Pacific softness, portfolio shifts and cost pressure keep execution in focus.

If you are wondering whether Johnson & Johnson stock still offers value after a long run, this article explains what the current price might be implying about the company. The stock last closed at US$258.51, with returns of 11.8% over 7 days, 14.7% over 30 days, 24.7% year to date, 73.5% over 1 year, 72.7% over 3 years, and 76.1% over 5 years. These returns naturally raise questions about what is already priced in. Recent market attention on Johnson & Johnson has centered on broader...

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Christina Zamarro will take over the role in July after spending nearly 20 years at Goodyear Tire & Rubber Company, most recently serving as its CFO.

Retirement planning usually starts with fear: housing, healthcare, and outliving the portfolio. Yet many of the moments people remember most have little to do with those necessities. Anniversary dinners. Birthday gifts for children and grandchildren. A weekend getaway. Tickets to a concert or ballgame. Funding those experiences from investment income, rather than repeatedly dipping into ... The Celebration Portfolio That Pays For Date Nights, Birthdays, And Anniversaries Forever

Given its significant hedge fund backing and attractive upside potential, Stereotaxis, Inc. (NYSEAMERICAN:STXS) is one of the most promising robotics stocks. Stereotaxis, Inc. (NYSEAMERICAN:STXS) is navigating a pivotal product transition, with fresh regulatory wins and a transformational acquisition reshaping its commercial runway, even as near-term results reflect the costs of that transition. Last month, Stereotaxis, […]

The Dow Jones Industrial Average topped 52000 for the first time on Monday, highlighting investors’ increasing demand for stocks at the heart of the American economy. One major contributor was Alphabet which rose 4.8% to lead gains on the Google-parent’s first day as one of the blue-chip index’s 30 components.

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.

This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

JNJ gets a positive CHMP opinion for Tecvayli in combination with Darzalex SC for treating relapsed/refractory multiple myeloma after one prior therapy.

SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.

A portfolio that throws off $60,000 a year sounds like a finished puzzle. The brokerage statement says $5,000 a month, the bills get paid, life goes on. Then the retiree adds up what actually reached the checking account and discovers the spendable amount is thousands of dollars lower than expected. Taxes, Medicare costs, and inflation ... Your Portfolio Pays $60,000 A Year. So Why Can You Only Spend $45,000?